DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20160788

Diagnostic performance of alpha-fetoprotein, YKL40 and GP73 in hepatocellular carcinoma Egyptian patients

Fahmy T. Ali, Mostafa M. Elhady, Amal M. Fawzy, Ahmed A. Abdelgawad

Abstract


Background: Hepatocellular carcinoma (HCC) is a primary malignancy of the liver. It is responsible for a large proportion of cancer deaths worldwide. Diagnosis of HCC often requires more sophisticated modalities and represents a challenge for physician.  

Methods: This study aimed to compare the diagnostic performance of AFP, YKL40 and GP73 in patients' serum with hepatocellular carcinoma (HCC) in high-risk population in an attempt to justify the new, sensitive, specific and rapid measure for the diagnosis and detection of HCC. Serum YKL40, GP73 and alpha-fetoprotein (AFP) were compared in a total of 60 human subjects in this study, including 20 healthy adults, and 40 patients with HCC, The main outcome measures were the specificity and sensitivity of YKL40 and GP73 in patients at risk for the development of HCC.

Results: Using 4.4 relative units as a cut-off value, the sensitivity and specificity of serum GP73 for HCC were 85% and 90% compared with 77% and 60% for YKL40 using 21.06 ng/ml as a cut-off value. On the same context, the sensitivity and specificity of serum AFP at 8.5ng/ml cut-off were 82% and 95%. While that for the AFP and GP73 combined detection was up to 92% and 96%, justifying that the combined detection could prevent the false negative diagnosis by any marker alone and significantly improve the detection rate of HCC.

Conclusions: The current evidence indicates that serum GP73 has HCC diagnostic efficacy inferior to that of AFP and YKL40 and the clinical implementation of serum GP73 measurement as a standard test for HCC is recommended alone or in combination with AFP.

 


Keywords


Hepatocellular carcinoma, AFP, YKL40 and GP73

Full Text:

PDF

References


Kamkar A, Rasheed A, Alsmadi1 O, Behbehani K. Insight into the impact of diabetes mellitus on the increased risk of hepatocel-lular carcinoma: mini-review. Journal of Diabetes & Metabolic Disor-ders. 2014:13:57.

Montella M, Crispo A, Giudice A. HCC, diet and metabolic factors. Hepat Mon. 2011;11:159-62.

Sanyal AJ, Yoon SK, Lencioni R. The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist. 2010;15:14-22.

Stefaniuk, P, Cianciara J, Wiercinska-Drapalo A. Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J Gastroenterol. 2010;16:418-24.

Shao Y, Chih-Hung H, Chenga A. Predictive Biomarkers of Antiangiogenic Therapy for Advanced Hepatocellular Carcinoma: Where Are We?. Liver Cancer. 2013;2:93-107.

Hu B, Tian X, Jie S, Xiangjun M. Evaluation of Individual and Combined Applications of Serum Biomarkers for Diagnosis of Hepatocellular Carcinoma: A Meta-Analysis. Int J Mol Sci. 2013;14:23559-80.

Zhu K, Dai1 Z, Zhou J. Biomarkers for hepatocellular car-cinoma: progression in early diagnosis, prognosis, and personalized therapy. Biomarker Research. 2013;1:10.

Kumar HA, Kumar JS, Mahavir Y, Archana T. Expression of YKL- 40, an Inflammatory Glycoprotein and its Prognostic Implica-tions in Cancer. J Mol Biomark Diagn. 2012;3:130. doi:10.4172/2155-9929.1000130.

Cintin C, Johansen JS, Christensen IJ, Price PA, Sorensen S. High serum YKL-40 level after surgery for colorectal carcinoma is re-lated to short survival. Cancer. 2002;95:267-74.

Zhu C, Wang C, Chen L-L, Ma G-L, Zhang S-C, et al. Serum YKL-40 Independently Predicts Outcome after Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma. PLoS ONE. 2012;7(9): e44648.

Broker M, Ijzermans J, Witjes C, van Vuuren H, de Man R. The Predictive Value of Golgi Protein 73 in Differentiating Benign from Malignant Liver Tumors. PLoS ONE. 2014;9(7):e100187.

Hu L, Yao W, Wang F, Rong X, Peng T. GP73 Is Upregulated by Hepatitis C Virus (HCV) Infection and Enhances HCV Secretion. PLoS ONE. 2014;9(3): e90553.

Reitman S, Frankel S. A colorimetric method for the de-termination of serum glutamic oxaloacetic and glutamic pyruvic transaminases. Am J Clin Pathol. 1957;28:56-63.

Kind P, King E. Estimation of plasma phosphatase by determination of hydrolyzed phenol with antipyrine. J Clin Pathol. 1954;7:322-6.

Perry B, Doumas BT, Buffone G, Glick M, Oy CN, Ryder K. Measurement of total bilirubin by use of bilirubin oxidase. Clin Chem. 1986;32(2):329-32.

D’Anzeo M, Faloppi L, Scartozzi M, Giampieri R, Bianconi M, Del Prete M, et al. The role of Micro-RNAs in Hepatocellular Carcinoma: From Molecular Biology to Treatment. Molecules. 2014;19:6393-6406.

Shang S, Plymoth A, Ge S. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology. 2012;55:483-90.

Tao LY, Cai L, He XD, Liu W, Qu Q. Comparison of serum tumor markers for intrahepatic cholangiocarcinoma and hepatocellu-lar carcinoma. Am Surg. 2011;76:1210-3.

Soresi M, Magliarisi C, Campagna P. Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res. 2003;23:1747-53.

Saffroy R, Pham P, Reffas M, Takka M, Lemoine A, Debuire B. New perspectives and strategy research biomarkers for hepatocellular carcinoma. Clin Chem Lab Med. 2007;45:1169-79.

Yoshida S, Kurokohchi K, Arima, K, Masaki T, Hosomi N, Fu-naki T, et al. Clinical significance of Lens culinaris agglutinin-reactive fraction of serum alpha-fetoprotein in patients with hepatocellular carcinoma. Int J Oncol. 2002;20:305-9.

Tangkijvanich P, Anukulkaarnkusol N, Suwangool P, Lertmaharit S, Hanvivatvong O, Kullavanijaya P, Poovorawan Y. CLINI-CAL characteristics and prognosis of hepatocellular carcinoma: analy-sis based on serum AFP levels. J Clin Gastroenterol. 2000;31:302-8.

Fujioka M, Nakashima Y, Nakashima O, Kojiro M. Im-munohistologic Study On The Expressions Of Alpha Fetoprotein And Protein Induced By Vitamin K Absence Or Antagonist Ii In Surgically Resected Small Hepatocellular Carcinoma. Hepatology. 2001;34(6):1128-34.

Debruyne E, Delanghe J. Diagnosing and monitoring hepatocel-lular carcinoma with alpha-fetoprotein: new aspects and applications. Clin Chim Acta. 2008;395:19-26.

Yamamoto K, Imamura H, Matsuyama Y. (2009): Significance of al-pha-fetopmtein and des-gamma-carbroxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. Ann Surg Oncol. 2009;16:2795-804.

Saito S, Ojima H, Ichikawa H, Hirohashi S, Kondo T. Molecular back global RNA expression analysis. Cancer Sci. 2008;99(12):2402-9.

Franca A, Elias J, Lima B, Martinnelli A, Carrilho F. Diagnostic staging and treatment of hepatocellular carcinoma. Braz J Med Biol Res. 2004;37:1689-1705.

Barletta E, Tinessa V, Daniele B. Screening of hepatocellular carcinoma: role of the alpha-fetoprotein (AFP) and ultrasonography (in Italian). Recenti Prog Med. 2005;96:295-9.

Volk M, Hernandez J, Su GL, Lok A, Marrero J Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark. 2007;3:79-87.

Farinati F, Marino D, De Giorgio M, Balden A, Cantarini M, Cursaro C, et al. Diagnostic and prognostic role of AFP in hepatocellular carcinoma: both or neither? Am J Gastroentrol. 2006;101(3): 524-32.

Johansen JS, Jensen BV, Roslind A. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Bi-omarkers Prev. 2006;15:194-202.

Yang D, Kim E, Pedersen R, Kim W, Pungpapong S. Utility of Serum YKL-40 as a Tumor-Specific Marker of Hepatobiliary Malignancies. Gut Liver. 2010;4:537-42.

Ringsholt M, Høgdall E, Johansen J, Paul A, Christensen Top of FormBottom of FormL. (2007): YKL-40 protein expression in normal adult human tissues – an immunohistochemical study. Journal of molecular histology. 2007;38(1):33-43.

Johansen J, Bojesen S, Mylin A, Frikke-Schmidt R, Price P, Nordest-gaard B. Elevated plasma YKL-40 predicts increased risk of gas-trointestinal cancer and decreased survival after any cancer diagnosis in the general population. J Clin Oncol. 2009;27:572-8.

Fritzsche FR, Riener MO, Dietel M, Moch H, Jung K, Kristiansen G. GOLPH2 expression in renal cell cancer. BMC Urol. 2008;8:15. DOI: 10.1186/1471-2490-8-15.

Shi Y, Chen J, Li L, Sun Z, Zen L, Xu S, et al. A study of diagnostic value of golgi protein GP73 and its genetic assay in primary hepatic carcinoma. Technol Cancer Res Treat. 2011;10:287-94.

Mao Y, Yang H, Xu H, Lu X, Sang X, Du S, et al. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut. Gut. 2010;59(12):1687-93.

ElShafie M, Fawzy A, Elhamy A, bbass S, Zakaria D, El Baz S. Golgi Protein 73 (GP73) as a Novel Serum Marker for Early Detection of Hepatocellular Carcinoma in Egyptian Patients. Life Science Jour-nal. 2012;9(2):823-30.

Li X, Wu K, Fan D. Serum Golgi Phosphoprotein 2 level: A better marker than alpha-fetoprotein for diagnosing early hepatocellular carcinoma. Hepatology. 2009;50:325-5.

Tian L, Wang Y, Xu D, Gui J, Jia X, Tong H, et al. Serological AFP/Golgi protein 73 could be a new diag-nostic parameter of hepatic diseases. Int J Cancer. 2011;129:1923-31.

Wang M, Long R, Comunale M, Junaidi O, Marrero J, di Bis-ceglie A, et al. Novel biomarkers for the early hepatocellular carcinoma. Cancer Epidemiol. Biomark Prev. 2009;18:1914-21.